PubMed Health⌕ Search

Biomedical subjects

W Sterner

Publications and source records attributed to W Sterner.

18 recordsLinked to original sources
PubMed1984

[The effectiveness and toxicity of a plant secretolytic agent and its component drugs].

The 50-fold human dosage of a physiomedical drug combination (VG I) (Sinupret) and their components (VG II-VG VI) in equivalent quantity, administered 10 times within 80 h, does not lead to unexpected and undesired effects on the parameters: rate of breathing, pulse rate, red blood count. Quick-%-value and the electrolytes calcium, potassium and sodium. Differences found in single drug groups are considered to be within the range. Concerning secretolytic effects, the drug combination and its components show significant activities performing a production rate of respective levels of 38.7% and 104% above the control groups.

Animals↗
PubMed1980

[Pharmacology and toxicology of etofylline clofibrate].

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was investigated in acute and chronic toxicity studies, using oral application. In addition studies in reproduction toxicology and safety pharmacology were performed. Under the conditions of the experiments the following important findings were observed: In the acute toxicity studies ML 1024 showed a dose-dependent symptomatology in all three species (rat, mouse, dog) used, no late mortalities occurred. As compared to the reference substances clofibric acid, clofibrate and etofylline, ML 1024 showed a considerably lower toxicity. The chronic studies over 6 months in mini-pigs and rats revealed that the liver was the target organ in both species. ML 1024 influenced the reproduction performance of the male and female rat. However, toxic dose levels were necessary to achieve those effects. In the teratogenic studies no teratogenic but some fetotoxic effects in the high dose level were observed. No effects could be observed in the peri- and postnatal experiment. The pharmacodynamic studies did not reveal any significant functional influences of ML 1024 on the major organs and organ systems.

Animals↗
PubMed1980

[Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].

Efficacy of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) and its molecule components (metabolites) of structurally similar theophylline esters and of clofibrate as standard was investigated in the artificial hyperlipidaemia of the rat. In accordance with former results etofylline clofibrate was antilipaemically active and, in contrast to similar esters and clofibrate, significantly decreased the cholesterol level. An investigation of the efficacy of its metabolites, either alone or in equivalent mixture, as well as of the standard clofibrate under fat diet demonstrated low efficacy of etofylline, but an increased activity in combination with clofibrate or clofibric acid. The activity of the combination is significantly superior to that of clofibrate under fat diet, but not under normal diet. The increased efficacy of etofylline clofibrate is undoubtedly an unusual potentiation, an additive effect of the metabolites can be excluded. Cholesterol and triglycerides are relevant parameters for the experimental evaluation of the efficacy. Measurement of total lipids offers no additional information. Substitution of triglycerides by total-beta-lipoproteins as parameter seems methodically useful, since values of cholesterol, triglycerides and beta-lipoproteins correlate well under normal diet.

Animals↗
PubMed1977

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024), a new hypolipemic agent.

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024) was tested on acute and chronic toxicity, on teratogenesis and fetotoxicity, on blood pressure and blood flow behaviour, on hypolipemic activity and general pharmacological behaviour in a screening test using 54 parameters. Results warrant further investigation of the potential therapeutic application of ML 1024 in humans based on its superiority to the well-known antilipemic clofibrate (CPIB).

Animals↗
PubMed1975

[Investigations on the mutagenic effect of triethylenemelamine (TEM) on early embryonic tissue and bone marrow of the rat by chromosome analysis (author's transl)].

Female rats were treated with triethylenemelamine (Tretamine; TEM) with a dose of 0.4 mg/kg body weight and 0.6 mg/kg body weight respectively on days 1, 2, 3; 3, 4, 5 or 6, 7, 8 post coitum. The animals were slaughtered on day 9 or pregnancy. Corpora lutea and living and dead embryos were counted to estimate embryonic loss. Thereafter chromosome-analysis of bone marrow cells and embryonic tissue took place. Highter TEM dosage increased the rate of embryonic loss. It increased from 28.1% with a dose of 3 X 0.4 mg TEM to 75.7% with 3 X 0.6 mg TEM. The level of embryonic loss depends on the time of treatment during different stages of early gestation. It was highest on the first 3 days and lowest on days 6-8 of gestation (0.4 mg TEM on -ays 1, 2, 3 p.c., 71.8%; 0.4 mg TEM on days 6, 7, 8 p.c., 2.9%). By the chromosome analysis, early embryonic tissue seemed to be more sensitive to TEM than bone marrow cells. The highest rates of numerical (35.7%) and (3 X 0.4 mg TEM). A higher dose induced a negative dose-effect, the frequency of aberrations decreased (3 X 0.6 mg TEM, 29% NUMERICAL AND 1.2% STRUCTURal aberrations). With increased embryonic loss (from 28.1% to 75%) structural aberrations decreased (from 5.7% to 1.2%). The time of treatment p.c. was highly correlated with the frequency of aberrations. It was highest with TEM application on days 6, 7, 8 of pregnancy; at the same time the mortality rate was lowest. The same tendencies were noted in the investigation of the chromosomes from bone marrow cells.

Animals↗